Debbie Rigby rounds up the latest in research news
Drugs can be used to treat acute migraine, or they can be used prophylactically to reduce the frequency and severity of attacks. Addressing lifestyle triggers and comorbidities in patients with migraine can be particularly beneficial for patients. Depending on the individual triggers, behavioural and psychological strategies and physical therapy can help some patients. Treatments for acute migraine aim to abort the headache stage of migraine within 1–2 hours.
Aust Prescr 2020;43:148-51.
In this meta-analysis of 17 randomized controlled trials, long-term use of ICSs did not increase the risk of URTI in patients with COPD. Short-term use of high-dose fluticasone increased the risk of URTI in patients with COPD, but not mometasone or budesonide, regardless of dose or duration.
BMC Pulmonary Medicine 2020;20:282.
A UK multicentre, randomised, double-blind, placebo-controlled randomised trial (n=306) explored the off-label use of gabapentin in women with chronic pelvic pain for more than 3 months. Gabapentin was titrated to a dose of 2700mg daily. There was no difference in mean numerical pain scores, mean change from baseline, or mean worst pain scores; and significantly more adverse effects including visual disturbances, dizziness, and drowsiness.
The use of testosterone for therapeutic purposes in women has been controversial. Menopausal hormone therapy with estrogen with or without progestogen should be considered initially in all post-menopausal women who present with low libido before the initiation of testosterone. Bio-identical and compounded testosterone products are not recommended. An algorithm for testosterone therapy for post-menopausal women is proposed in this article.